Carlos R. Camozzi

Group Chief Medical Officer

Back to Speakers

Group Chief Medical Officer with world-wide responsibility for the Clinical Research, Development and Pharmacovigilance activities of Simbec-Orion Group (London/Slough, United Kingdom); a clinical research organisation bringing outstanding solutions to the most challenging clinical research and development projects of the biotechnology and pharmaceutical industry.

A physician by training, with specialisations in Paediatrics, Clinical Pharmacology and Neuropsychiatry, Carlos has extensive experience in clinical research and development for paediatric and rare diseases therapeutic options, He also brings experience from successful regulatory interactions and outstanding products approvals achievements, both by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), including the first ever approval of a Gene Therapy (Glybera) in the western world. He also actively participated in financial activities, due diligences, fundraising rounds, and collaboration with several worldwide VCs in products review and analysis of innovative “orphan drugs” development strategies.